山東墨龍(002490.SZ):2019年度擬核銷壞賬3598.74萬元
格隆匯2月26日丨山東墨龍(002490.SZ)公佈,公司於2020年2月26日分別召開第六屆董事會第二次臨時會議和第六屆監事會第一次臨時會議,審議通過了《關於2019年度核銷壞賬的議案》。
根據《企業會計準則》、《關於進一步提高上市公司財務信息披露質量的通知》和《深圳證券交易所中小企業板上市公司規範運作指引》等相關規定要求,為真實反映公司財務狀況,公司按照依法合規、規範操作、逐筆審批、賬銷案存的原則,擬對截止2019年12月31日已全額計提壞賬準備且追收無果的部分其他應收款(共20筆,合計金額3598.74萬元)予以核銷。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.